HemoSense Signs $8 Million Senior Loan Financing Agreement

  
    
  
  
    
      HemoSense, Inc. (AMEX:HEM) today announced that it has signed an 
      $8 million extension in senior loan financing by expanding an existing 
      growth capital agreement with Lighthouse Capital Partners. The original 
      loan agreement with Lighthouse Capital Partners was initiated in early 
      2004, prior to the Company’s IPO in June 2005. 
      Under this new financing commitment, HemoSense has drawn down $5 million 
      for working capital purposes.
    
    
      “We have enjoyed a strong working relationship 
      with Lighthouse Capital Partners, and are pleased that they maintain 
      confidence in our technology and the market opportunity,” 
      said Jim Merselis, President and CEO of HemoSense. “We 
      intend to use this working capital to continue to expand operations and 
      develop the market for our INRatio® blood 
      coagulation monitoring system.”
    
    
      About HemoSense
    
    
      HemoSense develops, manufactures and markets easy-to-use, handheld blood 
      coagulation systems for monitoring patients taking warfarin. The 
      HemoSense INRatio system, used by healthcare professionals and patients 
      themselves, consists of a small monitor and disposable test strips. It 
      provides accurate and convenient measurement of blood clotting time, or 
      PT/INR values. Routine measurements of PT/INR are necessary for the safe 
      and effective management of the patient’s 
      warfarin dosing. INRatio is sold in the United States and 
      internationally. For more information, visit www.hemosense.com.
    
    
      This press release contains forward-looking statements within the 
      meaning of the U.S. Private Securities Litigation Reform Act of 1995. 
      Statements in this press release regarding the Company’s 
      business that are not historical facts may be “forward-looking 
      statements” that involve risks and 
      uncertainties. Specifically, the statements regarding the Company’s 
      ability to expand operations and develop the market for the INRatio 
      system are forward-looking statements within the meaning of the Safe 
      Harbor. Forward-looking statements are based on management’s 
      current, preliminary, expectations and are subject to risks and 
      uncertainties which may cause the actual results to differ materially 
      from the statements contained herein. Further information on the Company’s 
      business and risk factors are detailed in its filings with the 
      Securities and Exchange Commission, including its Form 10-Q for the 
      quarter ended June 30, 2006 filed on August 11, 2006. Undue reliance 
      should not be placed on these forward-looking statements, which speak 
      only as of the date they are made. The Company undertakes no obligation 
      to update publicly any forward-looking statements to reflect new 
      information, events or circumstances after the date they were made, or 
      to reflect the occurrence of unanticipated events.
    
    
      HemoSense® and INRatio® 
      are registered trademarks of HemoSense, Inc.